(LVOTO) either at rest or with provocation is present in nearly %75 of patients with HCM. The presence of a peak LVOT gradient of ≥ 30 mm Hg is considered to be indicative of obstruction, with resting or provoked gradients ≥ 50 mm Hg generally considered to be the threshold for septal reduction therapy (SRT) in those patients with drug-refractory symptoms. In patients with HCM in whom SRT is indicated, the procedure should be performed at experienced centers (comprehensive or primary HCM centers) with demonstrated excellence in clinical outcomes for these procedures. In adult patients with symptomatic obstructive HCM in whom surgery is contraindicated or the risk is considered unacceptably high because of serious comorbidities or advanced age, alcohol septal ablation when feasible and performed in experienced centers becomes the preferred invasive strategy for relief of LVOTO. Septal reduction by alcohol septal ablation (ASA) avoids sternotomy and, generally, patients experience less pain. Septal reduction by ASA is also advantageous in patients whose frailty or comorbid conditions increase the risk of surgical myomectomy. In centers with experienced interventional teams, procedural mortality of ASA is low (<1%). Alcohol septal ablation is a catheter-based intervention that relies on the injection of absolute alcohol into the septal perforator to induce a controlled infarction of the hypertrophied septum and consequently abolish the dynamic outflow obstruction.
You can also join this program via the mobile app.
Already a participant? Log in